Market Cap 57.34B
Revenue (ttm) 21.84B
Net Income (ttm) 1.68B
EPS (ttm) N/A
PE Ratio 13.90
Forward PE 13.50
Profit Margin 7.68%
Debt to Equity Ratio 0.69
Volume 2,494,100
Avg Vol 2,156,548
Day's Range N/A - N/A
Shares Out 285.42M
Stochastic %K 87%
Beta 0.25
Analysts Sell
Price Target $200.90

Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 201 847 6800
Website: www.bd.com
Address:
1 Becton Drive, Franklin Lakes, United States
deacon_mcclain
deacon_mcclain Dec. 12 at 5:04 PM
$BDX Mainz Biomed is attacking the right niche, non invasive CRC screening where adoption is driven by guidelines and population, not hype, and the TAM math starts with ~1.93M new CRC cases worldwide per year
0 · Reply
AmbNelson
AmbNelson Dec. 12 at 4:48 PM
$BDX You can call it noise, I call it base building Next NRG still holds 1.68–1.70 after four days up and 2x avg volume with $7.51M Nov +271% YoY, $7.39M Oct +196%, $7.07M Sep +229%, $7.51M Aug +222% and two 28yr microgrids locked this is the kind of backdrop that explodes when the next buyers step in
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:47 PM
Actionable Trade Alert for $BDX: Market Context: $BDX is currently trading at $198.08, showing strength as it approaches its 60D high of $200.08. The RSI at 62.79 indicates bullish momentum but is nearing overbought territory. The moving averages (MA30 at 188.82 and MA50 at 188.66) suggest a strong upward trend, providing support below current price levels. Directional Bias: The bullish trend is supported by the proximity to the 60D high and the positive positioning of the moving averages. The price is above both the MA30 and MA50, reinforcing a bullish outlook. Trade Plan: - Suggested Entry: $198.50 - Stop Loss: $195.00 (risking $3.50) - Take Profit Targets: 1. $202.00 (Target 1: 1.5% ROI) 2. $205.00 (Target 2: 3.4% ROI) 3. $232.00 (Target 3: 17.1% ROI) This plan provides a solid risk-reward ratio while capitalizing on the current bullish trend. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Dec. 10 at 6:21 PM
$BDX flying today. These calls doubled
0 · Reply
Thricejp1
Thricejp1 Dec. 10 at 5:35 PM
$BDX yep
0 · Reply
IP4you
IP4you Dec. 10 at 5:10 PM
$BDX target still is 220 by February - upgrades, company is doing buy backs and dust settling on some litigation. Rate cuts should help too.
0 · Reply
Palantir500
Palantir500 Dec. 10 at 4:42 PM
$BDX Nice move today!!
0 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 4:20 PM
$BDX I averaged down a little on those calls yesterday. working out. But I'm looking for a breakout move. Today: Jefferies Adjusts PT on Becton, Dickinson and Co. to $220 From $215, Maintains Buy Rating
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:51 AM
Actionable Trade Alert for $BDX: Market Context: $BDX is currently trading at $188.83, with an RSI of 43.28 indicating a neutral to slightly bearish sentiment. The stock is positioned near its 30-day moving average (MA30) of $187.79 and slightly below its 50-day moving average (MA50) of $188.3, suggesting potential resistance ahead. Directional Bias: The stock is within a range between its 60-day high of $196.36 and low of $162.29. Given the current RSI and proximity to moving averages, a bullish reversal could be anticipated if it breaks above the MA50. Trade Plan: - Suggested Entry: $189.50 (above MA30 and MA50) - Stop Loss: $185.00 (below recent support) - Take Profit Targets: 1. $194.00 (2.6% gain) 2. $198.00 (4.4% gain) 3. $221.00 (17% gain) This plan offers a favorable risk-reward ratio, with the potential for a significant return on the third target. Monitor closely for market movements. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 9 at 10:29 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BDX $185.00 Put · DEC 19, 2025 Exp Entry Price: $1.30 - $1.45 Exit Price Target: $2.08 Profit Margin: +60% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Latest News on BDX
Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 14 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


BD Board Increases Dividend for 54th Consecutive Year

Nov 6, 2025, 6:25 AM EST - 5 weeks ago

BD Board Increases Dividend for 54th Consecutive Year


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 6 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 6 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BKH


Becton Dickinson's CFO to depart

Oct 15, 2025, 4:42 PM EDT - 2 months ago

Becton Dickinson's CFO to depart


BD Announces CFO Transition Plan

Oct 15, 2025, 4:15 PM EDT - 2 months ago

BD Announces CFO Transition Plan


Best Dividend Aristocrats For October 2025

Sep 28, 2025, 1:00 AM EDT - 2 months ago

Best Dividend Aristocrats For October 2025

ABT ADP ATO BEN CAH CHRW CL


Best Dividend Aristocrats For September 2025

Aug 27, 2025, 2:09 PM EDT - 3 months ago

Best Dividend Aristocrats For September 2025

ABBV ABT ADM ADP AFL ALB AMCR


Best Dividend Kings: August 2025

Aug 24, 2025, 10:13 PM EDT - 3 months ago

Best Dividend Kings: August 2025

ABBV ABM ABT ADM AWR BKH CINF


Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

Aug 18, 2025, 8:00 AM EDT - 4 months ago

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat


BD to Present at Wells Fargo 2025 Healthcare Conference

Aug 14, 2025, 4:15 PM EDT - 4 months ago

BD to Present at Wells Fargo 2025 Healthcare Conference


Becton Dickinson Q3 Beats Estimates On Medical Device Boom

Aug 7, 2025, 11:40 AM EDT - 4 months ago

Becton Dickinson Q3 Beats Estimates On Medical Device Boom


BD Reports Third Quarter Fiscal 2025 Financial Results

Aug 7, 2025, 6:30 AM EDT - 4 months ago

BD Reports Third Quarter Fiscal 2025 Financial Results


deacon_mcclain
deacon_mcclain Dec. 12 at 5:04 PM
$BDX Mainz Biomed is attacking the right niche, non invasive CRC screening where adoption is driven by guidelines and population, not hype, and the TAM math starts with ~1.93M new CRC cases worldwide per year
0 · Reply
AmbNelson
AmbNelson Dec. 12 at 4:48 PM
$BDX You can call it noise, I call it base building Next NRG still holds 1.68–1.70 after four days up and 2x avg volume with $7.51M Nov +271% YoY, $7.39M Oct +196%, $7.07M Sep +229%, $7.51M Aug +222% and two 28yr microgrids locked this is the kind of backdrop that explodes when the next buyers step in
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:47 PM
Actionable Trade Alert for $BDX: Market Context: $BDX is currently trading at $198.08, showing strength as it approaches its 60D high of $200.08. The RSI at 62.79 indicates bullish momentum but is nearing overbought territory. The moving averages (MA30 at 188.82 and MA50 at 188.66) suggest a strong upward trend, providing support below current price levels. Directional Bias: The bullish trend is supported by the proximity to the 60D high and the positive positioning of the moving averages. The price is above both the MA30 and MA50, reinforcing a bullish outlook. Trade Plan: - Suggested Entry: $198.50 - Stop Loss: $195.00 (risking $3.50) - Take Profit Targets: 1. $202.00 (Target 1: 1.5% ROI) 2. $205.00 (Target 2: 3.4% ROI) 3. $232.00 (Target 3: 17.1% ROI) This plan provides a solid risk-reward ratio while capitalizing on the current bullish trend. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Dec. 10 at 6:21 PM
$BDX flying today. These calls doubled
0 · Reply
Thricejp1
Thricejp1 Dec. 10 at 5:35 PM
$BDX yep
0 · Reply
IP4you
IP4you Dec. 10 at 5:10 PM
$BDX target still is 220 by February - upgrades, company is doing buy backs and dust settling on some litigation. Rate cuts should help too.
0 · Reply
Palantir500
Palantir500 Dec. 10 at 4:42 PM
$BDX Nice move today!!
0 · Reply
RonIsWrong
RonIsWrong Dec. 10 at 4:20 PM
$BDX I averaged down a little on those calls yesterday. working out. But I'm looking for a breakout move. Today: Jefferies Adjusts PT on Becton, Dickinson and Co. to $220 From $215, Maintains Buy Rating
1 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:51 AM
Actionable Trade Alert for $BDX: Market Context: $BDX is currently trading at $188.83, with an RSI of 43.28 indicating a neutral to slightly bearish sentiment. The stock is positioned near its 30-day moving average (MA30) of $187.79 and slightly below its 50-day moving average (MA50) of $188.3, suggesting potential resistance ahead. Directional Bias: The stock is within a range between its 60-day high of $196.36 and low of $162.29. Given the current RSI and proximity to moving averages, a bullish reversal could be anticipated if it breaks above the MA50. Trade Plan: - Suggested Entry: $189.50 (above MA30 and MA50) - Stop Loss: $185.00 (below recent support) - Take Profit Targets: 1. $194.00 (2.6% gain) 2. $198.00 (4.4% gain) 3. $221.00 (17% gain) This plan offers a favorable risk-reward ratio, with the potential for a significant return on the third target. Monitor closely for market movements. https://privateprofiteers.com
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 9 at 10:29 PM
Hedge Alert Live - Protect Your Portfolio Contract: $BDX $185.00 Put · DEC 19, 2025 Exp Entry Price: $1.30 - $1.45 Exit Price Target: $2.08 Profit Margin: +60% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
11thestate
11thestate Dec. 9 at 6:10 PM
$BDX has agreed to settle for $85M to resolve claims that it misled investors about safety and software issues affecting its Alaris infusion pump system. Who’s eligible? Anyone who purchased $BDX shares between November 5, 2019 and February 5, 2020. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $2.14 — but if only ~25% of eligible investors file, the effective payout could increase to $8.56. Can I still file? Yes — late claims are currently being accepted, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/bdx-shareholder-settlement
0 · Reply
SeanDavid
SeanDavid Dec. 9 at 12:24 AM
Big news for Omnicell today. Titan XT is live. Because Omnicell runs multiyear product cycles similar to iPhone, this launch matters. The last cycle ended a couple yrs ago. Today marks start of a new upgrade wave, which is important for bookings and backlog. Titan XT is the new automated system, and part of the story is OmniSphere, their cloud platform. It unifies pharmacy / nursing workflows, creates a connected medication network, and brings AI into inventory forecasting and task guidance. So this is big. They sit in a duopoly w Pyxis. However feedback for Pyxis is negative. As hospitals come up for renewal, they have a brand new unified offering against a lack luster competitive product. For $OMCL , looks like early feedback is strong. A system reported 70% time savings on cabinet restocking thanks to OmniSphere’s guided workflows. Investor lens: a new product cycle, shift to cloud intelligence, and platform that can keep compounding. Real step forward. __ $BDX $AAPL
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:38 PM
Actionable Trade Alert for $BDX: Market Context: $BDX is currently trading at $190.87, showing a neutral RSI of 49.78, indicating no immediate overbought or oversold conditions. The price is above the 30-day MA (187.78) and 50-day MA (188.23), suggesting a bullish short-term trend. The 60-day high of 196.36 presents a potential resistance level, while the low of 162.29 indicates a strong support zone. Directional Bias: Given the current position relative to the MAs and the neutral RSI, there is a slight bullish bias. The price is approaching the recent high, and a break could lead to upward momentum. Trade Plan: - Suggested Entry: $191.50 - Stop Loss: $187.00 (3.5% below entry) - Take Profit Targets: 1. $195.00 (1.3% gain) 2. $198.00 (3.9% gain) 3. $223.00 (16.3% gain) This plan offers a potential ROI of over 17% on the third target. Monitor closely for price action around the targets. https://privateprofiteers.com
0 · Reply
Jay2x
Jay2x Dec. 8 at 4:50 PM
$BDX pls reverse! 🙏
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:39 AM
Actionable Trade Alert for $BDX: Market Context: The last close for $BDX is $193.76, sitting near the 60D high of $196.36. The RSI of 51.49 indicates a neutral stance, suggesting potential for upward movement without being overbought. The MA30 and MA50 are both below the current price, indicating short-term bullish momentum. Directional Bias: Given the proximity to the 60D high and the neutral RSI, we maintain a bullish bias. The price is above both the MA30 and MA50, which supports this outlook. Trade Plan: - Suggested Entry: $194.50 - Stop Loss: $190.00 (3.5% below entry) - Take Profit Targets: 1. $198.00 (1.9% gain) 2. $201.00 (3.3% gain) 3. $227.00 (16.7% gain) With the potential to exceed a 17% ROI at the third target, this trade offers a favorable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 5:34 PM
$BDX strikes a new partnership — what does it mean for investors? 🤔 $BDX teams up with ChemoGLO to enhance drug contamination testing, aiming to boost its MDS business unit and strengthen market position. The collaboration is expected to speed up and improve safety measures in healthcare settings. Discover the potential impact on BD's future here 👉 https://www.zacks.com/stock/news/2800517/bd-stock-up-post-tie-up-to-expand-hazardous-drug-contamination-testing?cid=sm-stocktwits-2-2800517-body-23690&ADID=SYND_STOCKTWITS_TWEET_2_2800517_BODY_23690
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 4:34 PM
$BDX popping after a smart strategic tie-up. The company’s teaming with ChemoGLO to expand hazardous drug contamination testing — a clear push to strengthen safety across healthcare environments. Get the full breakdown here 👉 https://www.zacks.com/stock/news/2800517/bd-stock-up-post-tie-up-to-expand-hazardous-drug-contamination-testing?cid=sm-stocktwits-2-2800517-teaser-23668&ADID=SYND_STOCKTWITS_TWEET_2_2800517_TEASER_23668
0 · Reply
RonIsWrong
RonIsWrong Dec. 5 at 3:26 PM
$BDX should pay well if this breaks out
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 2:54 PM
$BDX 👀 unusual options activity 10K March $220 calls
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 4 at 7:55 AM
Hedge Alert Live - Protect Your Portfolio Contract: $BDX $190.00 Put · DEC 19, 2025 Exp Entry Price: $2.64 - $2.85 Exit Price Target: $4.99 Profit Margin: +89% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
erevnon
erevnon Dec. 2 at 6:29 PM
Morgan Stanley maintains Becton Dickinson $BDX at Overweight and raises the price target from $197 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:29 PM
Morgan Stanley updates rating for Becton Dickinson ( $BDX ) to Overweight, target set at 197 → 210.
0 · Reply